Imatinib: Difference between revisions

Line 6:

* Date of FDA Approval (Expiration): 2001 (2015)

* 2009 Global Sales: $3.9 Billion

* Importance: It is one of the best selling [[cancer]] drugs of all time. It was the drug to be approved from the tyrosine kinase inhibitor class of drugs. It is very specific receptor tyrosine kinase (RTK) inhibitor, binding to Abl, PDGFR and KIT with far greater specificity than other RTKs, helping explain its relatively low impact side effect profile. ~~Although now considered hyperbole, TIME magazine declared that Gleevec was "converting a fatal cancer into a manageable chronic condition."~~ Has generated significant controversy due to its nearly $65,000 per year cost at a time when global health care budgets are being stretched thin.<ref>A Conversation With Brian J. Druker, M.D., Researcher Behind the Drug Gleevec by Claudia Dreifus, The New York Times, November 2, 2009</ref>

* Importance: It is one of the best selling [[cancer]] drugs of all time. It was the drug to be approved from the tyrosine kinase inhibitor class of drugs. It is very specific receptor tyrosine kinase (RTK) inhibitor, binding to Abl, PDGFR and KIT with far greater specificity than other RTKs, helping explain its relatively low impact side effect profile. Has generated significant controversy due to its nearly $65,000 per year cost at a time when global health care budgets are being stretched thin.<ref>A Conversation With Brian J. Druker, M.D., Researcher Behind the Drug Gleevec by Claudia Dreifus, The New York Times, November 2, 2009</ref>

* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 6: / Line 6: @@
 * Date of FDA Approval (Expiration): 2001 (2015)
 * 2009 Global Sales: $3.9 Billion
-* Importance: It is one of the best selling [[cancer]] drugs of all time. It was the drug to be approved from the tyrosine kinase inhibitor class of drugs. It is very specific receptor tyrosine kinase (RTK) inhibitor, binding to Abl, PDGFR and KIT with far greater specificity than other RTKs, helping explain its relatively low impact side effect profile. Although now considered hyperbole, TIME magazine declared that Gleevec was "converting a fatal cancer into a manageable chronic condition." Has generated significant controversy due to its nearly $65,000 per year cost at a time when global health care budgets are being stretched thin.<ref>A Conversation With Brian J. Druker, M.D., Researcher Behind the Drug Gleevec by Claudia Dreifus, The New York Times, November 2, 2009</ref>
+* Importance: It is one of the best selling [[cancer]] drugs of all time. It was the drug to be approved from the tyrosine kinase inhibitor class of drugs. It is very specific receptor tyrosine kinase (RTK) inhibitor, binding to Abl, PDGFR and KIT with far greater specificity than other RTKs, helping explain its relatively low impact side effect profile. Has generated significant controversy due to its nearly $65,000 per year cost at a time when global health care budgets are being stretched thin.<ref>A Conversation With Brian J. Druker, M.D., Researcher Behind the Drug Gleevec by Claudia Dreifus, The New York Times, November 2, 2009</ref>
 * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders